Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose
暂无分享,去创建一个
C. Stroh | G. Falchook | P. Girard | A. Johne | M. Friese-Hamim | S. el Bawab | W. Xiong | M. Klevesath | David S. Hong